We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (MEFOX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05212012
Recruitment Status : Recruiting
First Posted : January 27, 2022
Last Update Posted : April 28, 2022
Sponsor:
Collaborator:
Deutsche Krebshilfe e.V., Bonn (Germany)
Information provided by (Responsible Party):
AIO-Studien-gGmbH

Brief Summary:

This is a phase I/II-trial with D,L-methadone and mFOLFOX6 in the treatment of patients with histologically confirmed chemo-refractory colorectal carcinoma.

The aim of the phase-I trial is to evaluate the toxicity-profile and the dose-limiting toxicity of D,L-methadone combined with mFOLFOX6. Furthermore, to estimate the maximum tolerated dose and the recommended dose for phase-II-trial in the treatment of patients with histologically confirmed colorectal carcinoma not amenable to or progressing while having received all standard therapies.

The primary endpoint of the randomized phase-II study is to determine the disease control rate 12 weeks after randomization of patients with histologically confirmed advanced colorectal carcinoma upon treatment with D,L methadone plus mFOLFOX6 versus mFOLFOX6 alone. Overall response rate according to RECIST1.1, progression free survival (PFS), overall survival (OS), quality of life (QoL) according to the EORTC QLQc30 questionnaire, patient-reported outcomes and safety will be evaluated as secondary objectives.


Condition or disease Intervention/treatment Phase
Chemo-refractory Colorectal Carcinoma Drug: Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml) Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Phase I: 3+3 dose escalation study (non-randomized) - max. 18 participant

after Phase I start with a Amendment Phase II: Open-label, 2:1 randomized, controlled trial - 64 participant Patients in the mFOLFOX6 alone arm are allowed to cross over and receive methadone hydrochloride in combination with mFOLFOX6 upon disease progress

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer - The AIO-MEFOX Trial (AIO-KRK-0119)
Actual Study Start Date : February 17, 2022
Estimated Primary Completion Date : June 15, 2025
Estimated Study Completion Date : June 15, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: D,L-methadonehydrochloride + mFOLFOX6

Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)

Treatment with mFOLFOX6 every two weeks; will be administered:

Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1) LV at a dose of 400 mg/m² iv over two hours (day 1) 5-FU at a dose of 2400 mg/m² iv over 46 hours (day 1-3)

Drug: Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)
Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)




Primary Outcome Measures :
  1. Evaluation of the recommended dose for phase-II-trial [ Time Frame: 18 months ]
    Evaluation of the toxicity-profile of D,L-methadone and the dose-limiting toxicity (DLT) in combination with mFOLFOX6

  2. Disease control rate 12 weeks after randomization (ITT-population) [ Time Frame: 12 weeks after randomization ]
    Evaluation of the disease control rate of D,L-methadone plus mFOLFOX6 compared to mFOLFOX6 alone in the treatment of patients with advanced colorectal cancer. The disease control rate is defined as response (CR or PR) or stabilization (SD) of the tumor disease at 12 weeks after randomization (DCR) according to RECIST1.1.


Secondary Outcome Measures :
  1. Disease control rate (DCR) 12 weeks after randomization (per-protocol-population) [ Time Frame: 12 weeks ]
    The disease control rate is defined as response (CR or PR) or stabilization (SD) of the tumor disease at 12 weeks after randomization (DCR) according to RECIST1.1

  2. Overall response rate [ Time Frame: 46 months ]
    All tumor evaluation is performed according to RECIST 1.1

  3. patient diary [ Time Frame: 46 months ]
    Collection compliance with a diary

  4. Progression-free survival [ Time Frame: after 46 months ]
    Progression-free survival (PFS) will be defined as the time from randomization to the time of progress (according to RECIST 1.1) or death, or to the date of last tumor assessment without any such event (censored observation)

  5. Overall survival [ Time Frame: 46 months ]
    The duration of overall survival (OS) will be determined by measuring the time interval from randomization to the date of death or last observation (censored)

  6. Quality of life assessment [ Time Frame: 46 months ]

    EORTC QLQ-C30 ("European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30)" ).

    The EORTC QLQ-C30 is composed of a global health status/QoL-score, five function scales, three symptom scales and five single items (dyspnea, insomnia, appetite loss, constipation, diarrhea). Each item has four response alternatives: (1) "not at all", (2) "a little", (3) "quite a bit", and (4) "very much" - except the two items of the global health-status/quality of life scale which have response options ranging from (1) "very poor" to (7) "excellent".


  7. Adverse events [ Time Frame: 46 months ]
    Evaluation of the safety- and tolerability profile



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced, histologically confirmed, metastatic colorectal carcinoma not suitable for resection and chemorefractory or Previously employed chemotherapy regimens and agents should comprise the following: Fluoropyrimidines, oxaliplatin, irinotecan, antiangiogenic agents (bevacizumab, aflibercept or ramucirumab), anti-EFGR-mAbs (in case of all-Ras-wildtype and left-sided primary tumor) and Trifluridin/Tipiracil (TAS102)
  • Microsatellite stable subset (MSS) of colorectal cancer
  • Prior antineoplastic therapy or radiochemotherapy is allowed up to two weeks prior to start of the study medication. However, for the phase II part of the trial, failure of this strategy must be confirmed. In case of prior radiotherapy/radiochemotherapy the target lesion used for tumor evaluation must not be in the radiation field.
  • There must be an oxaliplatin free period of at least 6 months prior to start of the study medication.
  • No polyneuropathy of > grade 1
  • Tumor-related ECOG performance status 0-2
  • Anticipated life expectancy ≥ 12 weeks
  • Creatinine clearance ≥ 30 ml/min
  • Serum total bilirubin level ≤ 3 x ULN.
  • ALT and AST ≤ 2.5 x ULN or ≤ 5.0 x ULN in the presence of liver metastasis (established after adequate biliary drainage)
  • White blood cell count ≥ 3.5 x 106/ml, neutrophil granulocytes count ≥ 1,5 x 106/ml, platelet count ≥ 100 x 106/ml
  • Pain that has to be controllable without concomitant use of opioids
  • Signed informed consent according to ICH/GCP and national/local regulations (participation in translational research is obligate)
  • None of the following concomitant medications: MAO-B-Inhibitors, strong inductors or inhibitors of CYP3A4, antiarrhythmic drugs of class I and III or other drugs that have potential for QT-prolongation
  • Age ≥ 18 years
  • At least one measurable target lesion according to RECIST 1.1. Pre-irradiated or locally treated lesions must not be used as target lesions.

Exclusion Criteria:

  • Microsatellite unstable CRC (MSIhigh)
  • Chronic infectious diseases, immune deficiency syndromes
  • Polyneuropathy >grade I according to CTCAE V4.03
  • Premalignant hematologic disorders, e.g. myelodysplastic syndrome
  • Disability to understand and sign written informed consent document
  • Past or current history of malignancies except for the indication under this study and curatively treated:

    • Basal and squamous cell carcinoma of the skin
    • In-situ carcinoma of the cervix
    • Other malignant disease without recurrence after at least 3 years of follow-up
  • Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment
  • History of or evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumor, seizure not controlled with standard medical therapy or history of stroke).
  • Severe non-healing wounds, ulcers or bone fractions
  • Evidence of bleeding diathesis or coagulopathy
  • Patients not receiving therapeutic anticoagulation must have an INR ≤ 1.4 or PTT ≤ 40 sec within 28 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution)
  • Major surgical procedures or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study.
  • Pregnancy or breastfeeding women.
  • Use of cannabinoids because of overlapping and /or potentiating of potential side effects
  • Concomitant daily use of opioids in the last 3 months including methadone prior start of study medication
  • Subjects with known allergies to the study drugs or to any of its excipients.
  • Treatment with another investigational drug or participation in another interventional trial (within the 14 days prior randomization or 5 plasma half-lifes of the used investigational drug, whatever is longer)
  • Congenital QT-syndrome.
  • Alcohol abuse.
  • Bronchial asthma.
  • Liver cirrhosis > Child-Pugh classification A.
  • Any psychological, familial, sociological or geographical condition potentially compromising compliance with the study protocol and the follow-up schedule; those conditions should be discussed with the patient prior to registration in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05212012


Contacts
Layout table for location contacts
Contact: AIO-Studien-gGmbH +49308145344 ext 70 info@aio-studien-ggmbh.de

Locations
Layout table for location information
Germany
Universitätsklinikum Hamburg Eppendorf - II. Med. Recruiting
Hamburg, Germany, 20246
Contact: Sinn, PD Dr.         
Universitätsklinikum Ulm - Innere Med. I Recruiting
Ulm, Germany, 89081
Contact: Seufferlein, Prof. Dr.         
Sponsors and Collaborators
AIO-Studien-gGmbH
Deutsche Krebshilfe e.V., Bonn (Germany)
Investigators
Layout table for investigator information
Principal Investigator: Thomas Seufferlein, Prof.Dr.med. Ulm University Hospital, Department of Internal Medicine I
Additional Information:
Layout table for additonal information
Responsible Party: AIO-Studien-gGmbH
ClinicalTrials.gov Identifier: NCT05212012    
Other Study ID Numbers: AIO-KRK-0119
2019-004158-26 ( EudraCT Number )
First Posted: January 27, 2022    Key Record Dates
Last Update Posted: April 28, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AIO-Studien-gGmbH:
chemo-refractory
colorectal carcinoma
D,L-methadone
mFOLFOX6
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Methadone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents